A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his ...

As of Friday, January 09, Rigel Pharmaceuticals, Inc.’s RIGL share price has dipped by 5.01%, which has investors questioning ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

Now, it’s worth noting Stock Advisor’s total average return is 966 % — a market-crushing outperformance compared to 194% for ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

As of Friday, January 02, Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 60.00%, which has investors ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...